Literature DB >> 11500417

Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.

J R Bosarge1, J M Watt, D O McDaniel, E Swiatlo, L S McDaniel.   

Abstract

Pneumococcal surface protein A (PspA) is a pneumococcal virulence factor capable of eliciting protection against pneumococcal infection in mice. Previous studies have demonstrated that the protection is antibody mediated. Here we examined the ability of pspA to elicit a protective immune response following genetic immunization of mice. Mice were immunized by intramuscular injections with a eukaryotic expression vector encoding the alpha-helical domain of PspA/Rx1. Immunization induced a PspA-specific serum antibody response, and immunized mice survived pneumococcal challenge. Survival and antibody responses occurred in a dose-dependent manner, the highest survival rates being seen with doses of 10 microg or greater. The ability of genetic immunization to elicit cross-protection was demonstrated by the survival of immunized mice challenged with pneumococcal strains differing in capsule and PspA types. Also, immunized mice were protected from intravenous and intratracheal challenges with pneumococci. Similar to the results seen with immunization with PspA, the survival of mice genetically immunized with pspA was antibody mediated. There was no decline in the level of protection 7 months after immunization. These results support the use of genetic immunization to elicit protective immune responses against extracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500417      PMCID: PMC98657          DOI: 10.1128/IAI.69.9.5456-5463.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.

Authors:  D S Fedson
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

3.  CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species.

Authors:  A K Yi; R Tuetken; T Redford; M Waldschmidt; J Kirsch; A M Krieg
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

4.  Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae.

Authors:  L S McDaniel; F Loechel; C Benedict; T Greenway; D E Briles; R M Conry; D T Curiel
Journal:  Gene Ther       Date:  1997-04       Impact factor: 5.250

5.  Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.

Authors:  Y H Chow; B L Chiang; Y L Lee; W K Chi; W C Lin; Y T Chen; M H Tao
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

6.  Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.

Authors:  M A Shelly; H Jacoby; G J Riley; B T Graves; M Pichichero; J J Treanor
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

7.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

Review 8.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

9.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

10.  Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.

Authors:  L S McDaniel; B A Ralph; D O McDaniel; D E Briles
Journal:  Microb Pathog       Date:  1994-11       Impact factor: 3.738

View more
  11 in total

1.  Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.

Authors:  Eliane N Miyaji; Daniela M Ferreira; Alexandre P Y Lopes; M Cristina C Brandileone; Waldely O Dias; Luciana C C Leite
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 2.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

3.  Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice.

Authors:  Lisa R Quin; Quincy C Moore; Larry S McDaniel
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniae.

Authors:  Quincy C Moore; LaShundra Johnson; Michael Repka; Larry S McDaniel
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

5.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

6.  Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil.

Authors:  Fabiana Cristina Pimenta; Fátima Ribeiro-Dias; Maria Cristina C Brandileone; Eliane N Miyaji; Luciana C C Leite; Ana Lúcia S Sgambatti de Andrade
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

7.  Enhanced protection against nasopharyngeal carriage of Streptococcus pneumoniae elicited by oral multiantigen DNA vaccines delivered in attenuated Salmonella typhimurium.

Authors:  Qiao Zhang; Qianli Ma; Qi Li; Wei Yao; Changzheng Wang
Journal:  Mol Biol Rep       Date:  2010-06-19       Impact factor: 2.316

8.  Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin.

Authors:  María del Mar García-Suárez; María Dolores Cima-Cabal; Noelia Flórez; Pilar García; Rafael Cernuda-Cernuda; Aurora Astudillo; Fernando Vázquez; Juan R De los Toyos; F Javier Méndez
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection.

Authors:  J Cao; D Li; Y Gong; N Yin; T Chen; C K Wong; W Xu; J Luo; X Zhang; C W K Lam; Y Yin
Journal:  Clin Exp Immunol       Date:  2009-02-11       Impact factor: 4.330

10.  Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.

Authors:  Daniela M Ferreira; Michelle Darrieux; Maria Leonor S Oliveira; Luciana C C Leite; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2008-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.